FDA Halcion EIR review involves Dept. of Justice, Upjohn discloses.
Executive Summary
FDA HALCION REVIEW INCLUDES JUSTICE DEPT. PARTICIPATION, Upjohn disclosed in a proxy statement for its proposed merger with Pharmacia. The proxy statement declares that FDA, "with the assistance of the U.S. Attorney's Office in Grand Rapids, Mich., is conducting a review of the FDA's prior inspection report on Halcion, including an assessment of the conclusions of the report, the approval of the drug, related FDA processes and procedures and the violations of any laws." The proxy continues: "Upjohn cannot predict the outcome of this review."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth